Physician
Radiology
Dr. David R. Betteridge, MD
|
|
Give Review
David Betteridge works in the field of Radiology. He researched medicine at Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School has a rank of 1 in research and a 12 in primary care David Betteridge is also a published MD. He has 100 publication published. The most recent publication is: Genetic influence on HDL cholesterol. He accepts all Medicare patients.
Publications
- Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients: A Meta-Analysis.
- Computer-controlled apparatus for automated development of continuous flow methods.
- An improved flow-through phototransducer.
- Treatment of lipid disorders in patients with diabetes.
- The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activiti...
- Influence of the alpha-adrenoreceptor naftopidil and doxazosin, on adrenaline-induced serotonin platelets: comparison with the antagonists, collagen and efflux by huma...
- The generation of the F(2)-isoprostane 8-epi-PGF(2alpha) by human platelets on collagen stimulation.
- Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
- Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
- Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk.
- Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CA...
- Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascu...
- Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
- Pioglitazone added to conventional lipid-lowering treatment in familial combined hyperlipidaemia improves parameters of metabolic control: relation to liver, muscle an...
- Native and oxidized low-density lipoproteins modulate the vasoactive actions of soluble beta-amyloid peptides in rat aorta.
- Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes.
- Effects of pioglitazone on lipid and lipoprotein metabolism.
- Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).
- Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< ...
- Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone.
- PROactive: time for a critical appraisal.
- Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11).
- The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).
- The effect of experimental diabetes on prostacyclin production by tissues from pregnant rats.
- Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: ...
- Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus.
- Elevated levels of authentic plasma hydroperoxides in NIDDM.
- Fish oils and cardiovascular disease.
- Hyperlipidaemia does not impair vascular endothelial function in glycogen storage disease type 1a.
- Platelet transmembrane signalling responses to collagen in familial hypercholesterolaemia.
- Diabetic dyslipidaemia: treatment implications.
- Platelet function in patients with hypercholesterolaemia.
- Diabetic dyslipidemia.
- Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.
- Cholesterol lowering and CHD prevention: time to get on with it.
- Decreased sensitivity to adenosine in platelets from patients with familial hypercholesterolaemia--a change reversed by cholestyramine treatment.
- Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level.
- Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association.
- Platelet phosphoinositidase C activity in familial hypercholesterolaemia.
- The influence of aspirin on plasma and platelet catecholamine levels, and platelet function in normal man.
- Ciprofibrate--a profile.
- Altered cellular signalling and decreased platelet sensitivity to adenosine in insulin-dependent diabetic patients with proliferative retinopathy.
- Review of new guidelines for management of dyslipidaemia.
- Apolipoprotein E genotyping in Alzheimer''s disease.
- Lipid management: past, present, and future.
- Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels.
- Lipids and atherogenesis in diabetes mellitus.
- Postprandial lipid metabolism and beta-cell function in non-insulin-dependent (type 2) diabetes mellitus after a mixed meal with a high fat content.
- Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
- Reduced platelet serotonin content and release in familial hypercholesterolaemia.
- In vitro adrenaline and collagen-induced mobilization of platelet calcium and its inhibition by naftopidil, doxazosin and nifedipine.
- Lipids and prevention in coronary care.
- Relationships between plasma measures of oxidative stress and metabolic control in NIDDM.
- LDL heterogeneity: implications for atherogenicity in insulin resistance and NIDDM.
- Drug therapy for coronary heart disease: the Sheffield table.
- Genetic influence on HDL cholesterol.
- Diabetic dyslipidaemia.
- Nutrition and therapeutics.
- International multicentre comparison of cerivastatin with placebo and simvastatin for the treatment of patients with primary hypercholesterolaemia. International Ceriv...
- Platelet aggregation may not be a prerequisite for collagen-stimulated platelet generation of nitric oxide.
- What is oxidative stress?
- Diabetes, coronary heart disease and sulphonylureas-not the final word.
- Status report of lipid-lowering trials in diabetes.
- Platelet noradrenaline and adrenaline efflux in hypercholesterolaemia: studies in platelet-rich plasma.
- Platelet secretion of beta-amyloid is increased in hypercholesterolaemia.
- Measures of oxidative stress in heterozygous familial hypercholesterolaemia.
- PPARS, insulin resistance and type 2 diabetes.
- Lipid-lowering trials in diabetes.
- The current management of diabetic dyslipidaemia.
- Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
- Regional myocardial blood flow and glucose utilization during fasting and physiological hyperinsulinemia in humans.
- An investigation into the mechanisms mediating plasma lipoprotein-potentiated beta-amyloid fibrillogenesis.
- A new drug target for treatment of dyslipidaemia associated with type 2 diabetes and the metabolic syndrome?
- Lipoprotein lipase gene variants relate to presence and degree of microalbuminuria in Type II diabetes.
- Differential actions of naftopidil, doxazosin and nifedipine on platelet thromboxane generation and platelet-derived growth factor efflux in vitro.
- Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance.
- Evaluation of methods for the extraction of nitrite and nitrate in biological fluids employing high-performance anion-exchange liquid chromatography for their determin...
- Mismatch between insulin-mediated glucose uptake and blood flow in the heart of patients with Type II diabetes.
- Plant sterols...from research to practice.
- Diabetes: a new challenge in the prevention of coronary heart disease.
- The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
- CHD and diabetes--target dyslipidaemia, reduce the risk.
- Human cytomegalovirus seropositivity is associated with impaired vascular function.
- Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry...
- Confirmed locus on chromosome 11p and candidate loci on 6q and 8p for the triglyceride and cholesterol traits of combined hyperlipidemia.
- Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia.
- Potentiation of beta-amyloid polymerisation by low-density lipoprotein enhances the peptide''s vasoactivity.
- Guidelines on the management of secondary prophylaxis of vascular events in stable patients in primary care.
- Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
- Plasma beta-amyloid (A beta) 40 concentration, lipid status and age in humans.
- Soluble beta-amyloid (A beta) 40 causes attenuation or potentiation of noradrenaline-induced vasoconstriction in rats depending upon the concentration employed.
- Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised plac...
- Exaggerated polymerisation of beta-amyloid 40 stimulated by plasma lipoproteins results in fibrillar Abeta preparations that are ineffective in promoting ADP-induced p...
- Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.
- Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory?
- Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study.
- Urinary 8-epi-PGF2alpha and its endogenous beta-oxidation products (2,3-dinor and 2,3-dinor-5,6-dihydro) as biomarkers of total body oxidative stress.
- Circulating vitamin E, transforming growth factor beta1, and the association with renal disease susceptibility in two racial groups with type 2 diabetes.
- Statins and diabetes.
Schools
Harvard Medical School
Mt Auburn Hospital
Massachusetts General Hospital
Doctors Specialties
- Diagnostic Radiology
- Radiology
Accepted Insurances
- Blue Card PPO
- CHAMPVA
- First Health (Coventry Health Care) PPO
- Humana
- Medicare MCR
- Medico
- POMCO Group
- Tufts PPO
- United Healthcare
Education
-
Massachusetts General Hospital -
Harvard Medical School
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1679553184 |
| Last Name Of The Provider | BETTERIDGE |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. David Rushforth, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James Galvin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David Dougherty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David M. Kelly Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tabita A. Wright, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John P. Keefe, MD |
|
|
Dr. Ronald P. Goldberg, MD |
|
|
Dr. Colleen J. Whitecar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen Trehu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gordon K. Kanzer, MD |